{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:18:49Z","timestamp":1790396329345,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","pediatr-neonatol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatrics & Neonatology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.pedneo.2014.10.006","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T09:48:06Z","timestamp":1419328086000},"page":"287-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-2735","authenticated-orcid":false,"given":"Shih-Hsiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pedneo.2014.10.006_bib1","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pedneo.2014.10.006_bib2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"M\u00f6ricke","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2014.10.006_bib4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(09)70228-1","article-title":"Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOF) protocol ALL-9 (1997\u20132004)","volume":"10","author":"Veerman","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib5","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/pbc.22620","article-title":"Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group","volume":"55","author":"Yamaji","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.pedneo.2014.10.006_bib7","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1200\/JCO.2011.40.5936","article-title":"Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia\u2013Singapore acute lymphoblastic leukemia 2003 study","volume":"30","author":"Yeoh","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/leu.2009.251","article-title":"Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia","volume":"24","author":"Schmiegelow","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2014.10.006_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/leu.2009.248","article-title":"Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia","volume":"24","author":"Liang","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2014.10.006_bib11","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pedneo.2014.10.006_bib12","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib13","first-page":"2619","article-title":"Inhibition of leukemias in man by l-asparaginase","volume":"27","author":"Oettgen","year":"1967","journal-title":"Cancer Res"},{"key":"10.1016\/j.pedneo.2014.10.006_bib14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-74-6-893","article-title":"l-asparaginase: clinical, biochemical, pharmacological, and immunological studies","volume":"74","author":"Capizzi","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pedneo.2014.10.006_bib15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.160.3827.533","article-title":"Asparagine synthetase activity of mouse leukemias","volume":"160","author":"Horowitz","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.pedneo.2014.10.006_bib16","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/0006-2952(69)90375-X","article-title":"l-asparaginase resistance in human leukemia\u2013asparagine synthetase","volume":"18","author":"Haskell","year":"1969","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib17","first-page":"294","article-title":"Biochemical characterization of U937 cells resistant to l-asparaginase: the role of asparagine synthetase","volume":"3","author":"Kiriyama","year":"1989","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2014.10.006_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/bj3570321","article-title":"Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells","volume":"357","author":"Aslanian","year":"2001","journal-title":"Biochem J"},{"key":"10.1016\/j.pedneo.2014.10.006_bib19","doi-asserted-by":"crossref","first-page":"C1691","DOI":"10.1152\/ajpcell.1997.272.5.C1691","article-title":"Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells","volume":"272","author":"Hutson","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib20","first-page":"4363","article-title":"In\u00a0vitro and in\u00a0vivo killing of acute lymphoblastic leukemia cells by l-asparaginase","volume":"49","author":"Asselin","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.pedneo.2014.10.006_bib21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana\u2013Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana\u2013Farber Cancer Institute All Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib23","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose l-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib24","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V90.7.2723","article-title":"In\u00a0vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia","volume":"90","author":"Kaspers","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib25","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/leu.2008.165","article-title":"Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study","volume":"22","author":"Appel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2014.10.006_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0140-6736(91)91029-T","article-title":"Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia","volume":"338","author":"Pieters","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.pedneo.2014.10.006_bib27","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3109\/10428194.2012.658570","article-title":"Clinical impact of in\u00a0vitro cellular drug resistance on childhood acute lymphoblastic leukemia in Taiwan","volume":"53","author":"Chen","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pedneo.2014.10.006_bib28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/73439","article-title":"A gene expression database for the molecular pharmacology of cancer","volume":"24","author":"Scherf","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.pedneo.2014.10.006_bib29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa033513","article-title":"Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment","volume":"351","author":"Holleman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pedneo.2014.10.006_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/0008-5472.291.65.1","article-title":"A genome-wide view of the in\u00a0vitro response to l-asparaginase in acute lymphoblastic leukemia","volume":"65","author":"Fine","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.pedneo.2014.10.006_bib31","first-page":"1094","article-title":"TEL\/AML1 gene fusion is related to in\u00a0vitro drug sensitivity for l-asparaginase in childhood acute lymphoblastic leukemia","volume":"96","author":"Ramakers-van Woerden","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib32","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1182\/blood-2002-08-2446","article-title":"Sensitivity to l-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL","volume":"101","author":"Stams","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/sj.leu.2403259","article-title":"Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by l-asparaginase in TEL\/AML1-positive leukaemic cells","volume":"18","author":"Krejci","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2014.10.006_bib34","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood-2004-10-3892","article-title":"Asparagine synthetase expression is linked with l-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia","volume":"105","author":"Stams","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1172\/JCI30235","article-title":"Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase","volume":"117","author":"Iwamoto","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pedneo.2014.10.006_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/pbc.21213","article-title":"Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines","volume":"50","author":"Su","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.pedneo.2014.10.006_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jprot.2007.11.009","article-title":"Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients","volume":"71","author":"Abbatiello","year":"2008","journal-title":"J Proteomics"},{"key":"10.1016\/j.pedneo.2014.10.006_bib38","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1182\/blood-2005-06-2597","article-title":"Up-regulation of asparagine synthetase expression is not linked to the clinical response l-asparaginase in pediatric acute lymphoblastic leukemia","volume":"107","author":"Appel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1042\/bj3580059","article-title":"Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells","volume":"358","author":"Aslanian","year":"2001","journal-title":"Biochem J"},{"key":"10.1016\/j.pedneo.2014.10.006_bib40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood-2005-07-2930","article-title":"The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia","volume":"107","author":"Holleman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib41","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.1158\/0008-5472.CAN-09-0800","article-title":"Adipocytes impair leukemia treatment in mice","volume":"69","author":"Behan","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.pedneo.2014.10.006_bib42","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/0008-5472.CAN-12-4402","article-title":"Adipocytes cause leukemia cell resistance to l-asparaginase via release of glutamine","volume":"73","author":"Ehsanipour","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.pedneo.2014.10.006_bib43","first-page":"283","article-title":"Single nucleotide polymorphism in the promoter region of asparagine synthetase and its impact on the gene expression","volume":"15","author":"Luo","year":"2007","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.pedneo.2014.10.006_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2010.256","article-title":"A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity","volume":"25","author":"Chen","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2014.10.006_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/clpt.2010.94","article-title":"Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity","volume":"88","author":"Chen","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pedneo.2014.10.006_bib46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"l-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.pedneo.2014.10.006_bib47","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib48","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1172\/JCI106579","article-title":"Immunological responses to l-asparaginase","volume":"50","author":"Peterson","year":"1971","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pedneo.2014.10.006_bib49","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/sj.leu.2401162","article-title":"Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia","volume":"12","author":"Woo","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2014.10.006_bib50","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","article-title":"Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana\u2013Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols","volume":"25","author":"Barry","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib51","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/10428190701292049","article-title":"The anti-asparagines antibodies correlate with l-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia","volume":"48","author":"Zalewska-Szewczyk","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pedneo.2014.10.006_bib52","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib53","first-page":"2561","article-title":"Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models","volume":"27","author":"Avramis","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pedneo.2014.10.006_bib54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s002800100286","article-title":"Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration","volume":"48","author":"Albertsen","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib55","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia","volume":"18","author":"Woo","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib56","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2014.10.006_bib57","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/sj.leu.2403011","article-title":"Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients","volume":"17","author":"Wang","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2014.10.006_bib58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/mpo.10096","article-title":"Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase","volume":"38","author":"Albertsen","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00280-002-0466-y","article-title":"Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study","volume":"50","author":"Klug Albertsen","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pedneo.2014.10.006_bib60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2141.2007.06763.x","article-title":"Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples","volume":"139","author":"Estes","year":"2007","journal-title":"Br J Haematol"}],"container-title":["Pediatrics & Neonatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875957214001983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875957214001983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T22:01:49Z","timestamp":1690754509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875957214001983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1875957214001983"],"URL":"https:\/\/doi.org\/10.1016\/j.pedneo.2014.10.006","relation":{},"ISSN":["1875-9572"],"issn-type":[{"value":"1875-9572","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance","name":"articletitle","label":"Article Title"},{"value":"Pediatrics & Neonatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pedneo.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}